Zhou J - Search Results

1

Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.

Zheng J, Cao H, Li Y, Rao C, Zhang T, Luo J, Lv D, Zhu Y, Zhou J, Zhou J. Zheng J, et al. Among authors: zhou j. Lung Cancer. 2020 Sep;147:130-136. doi: 10.1016/j.lungcan.2020.07.016. Epub 2020 Jul 16. Lung Cancer. 2020. PMID: 32702569

2

[The correlation between DNA content and Fas antigen in non-small cell lung cancer].

Yu W, Zhou J, Qiu H. Yu W, et al. Among authors: zhou j. Zhonghua Jie He He Hu Xi Za Zhi. 2002 Apr;25(4):210-3. Zhonghua Jie He He Hu Xi Za Zhi. 2002. PMID: 12133327 Chinese.

3

[The effect of silicon dioxide on the activation of nuclear factor-kappaB in THP-1 cells].

Zhou JY, Mao GG, Tang FD, Zhou JY. Zhou JY, et al. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2003 Jun;21(3):179-81. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2003. PMID: 14761478 Chinese.

4

Inhibitory effect of 1,8-cineol (eucalyptol) on Egr-1 expression in lipopolysaccharide-stimulated THP-1 cells.

Zhou JY, Wang XF, Tang FD, Zhou JY, Lu GH, Wang Y, Bian RL. Zhou JY, et al. Acta Pharmacol Sin. 2007 Jun;28(6):908-12. doi: 10.1111/j.1745-7254.2007.00555.x. Acta Pharmacol Sin. 2007. PMID: 17506951

5

[Expression of glucose transporter in non-small cell lung carcinoma and its clinical significance].

Lu GH, Zhong XJ, Ding W, Zhou JY. Lu GH, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2008 Mar;37(2):176-81. doi: 10.3785/j.issn.1008-9292.2008.02.013. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2008. PMID: 18422279 Chinese.

6

[hVEGF siRNA inhibits initial growth of A549 tumor cells in nude mice and angiogenesis on CAM assay].

Liu R, Ma WJ, Zhou JY, Yang GD, Zhou JY. Liu R, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009 Mar;38(2):136-44. doi: 10.3785/j.issn.1008-9292.2009.02.004. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009. PMID: 19363820 Chinese.

7

Activated changes of platelet ultra microstructure and plasma granule membrane protein 140 in patients with non-small cell lung cancer.

Zhuge Y, Zhou JY, Yang GD, Zu DL, Xu XL, Tian MQ, Lu GH. Zhuge Y, et al. Chin Med J (Engl). 2009 May 5;122(9):1026-31. Chin Med J (Engl). 2009. PMID: 19493436

8

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.

Zhao Q, Shentu J, Xu N, Zhou J, Yang G, Yao Y, Tan F, Liu D, Wang Y, Zhou J. Zhao Q, et al. Among authors: zhou j. Lung Cancer. 2011 Aug;73(2):195-202. doi: 10.1016/j.lungcan.2010.11.007. Epub 2010 Dec 8. Lung Cancer. 2011. PMID: 21144613 Clinical Trial.

9

[Correlation of the expression of III β-tubulin and MDR1 protein with biological features of non-small cell lung cancer].

Hu LH, Wu Y, Lu GH, Chen QY, Wang YH, Zhou JY. Hu LH, et al. Zhonghua Zhong Liu Za Zhi. 2010 Oct;32(10):762-6. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 21163067 Chinese.

10

Expression and clinical significance of ezrin in non--small-cell lung cancer.

Zhang XQ, Chen GP, Wu T, Yan JP, Zhou JY. Zhang XQ, et al. Clin Lung Cancer. 2012 May;13(3):196-204. doi: 10.1016/j.cllc.2011.04.002. Epub 2011 Dec 3. Clin Lung Cancer. 2012. PMID: 22137559

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55,094 results

Search Page

Filters